

Feb. 11 2008 01:50PM P4

RECEIVED  
CENTRAL FAX CENTER

FEB 11 2008

PTO/SB/08A (01-06)

Approved for use through 02/29/2008. CMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1448/PTO

### INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 2

**Complete if Known**

Application Number	10/510,877
Filing Date	10/06/2004
First Named Inventor	Mark Parrington
Art Unit	1642
Examiner Name	Sean E. Aeder
Attorney Docket Number	API-01-20-US

## U. S. PATENT DOCUMENTS

[illegible]

**FOREIGN PATENT DOCUMENTS**

[illegible]

Examiner Signature	Date Considered
-----------------------	--------------------

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPER 8.06. One line through citation if not in conformance and not considered. Indicate copy of form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Code of USPTO Patent Documents at [www.uspto.gov/patents/basics/kindscode.htm](http://www.uspto.gov/patents/basics/kindscode.htm). <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.31). <sup>4</sup> For Japanese prior art documents, the expiration of the year of the grant of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by Japanese office. <sup>6</sup> The appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>7</sup> Applicant is to place a check mark here if English language Japanese paper is attached.

Transmittal is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is the file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 42 and 37 CFR 1.44. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments, suggestions, or requests for change should be sent to the USPTO. To complete this form earlier or request suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. Do not send fees or completed forms to this address. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

RECEIVED  
CENTRAL FAX CENTER

FEB 11 2008

PTO/SB/08B (01-08)

Approved for use through 02/29/2008. OMB 0661-0031  
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

## Complete If Known

Application Number	10/510,677
Filing Date	10/06/2004
First Named Inventor	Mark Parrington
Art Unit	1642
Examiner Name	Sean E. Aeder
Attorney Docket Number	API-01-20-US

Sheet 2 of 2

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		Beauchemin, et al. Isolation and Characterization of Full-Length Functional cDNA Clones for Human Carcinoembryonic Antigen. Mol. Cell. Biol., Sept. 1987, pp. 3221-3230	
		Kim, et al. EMBL Accession No. BM752131 (March 9, 2002)	
		Marshall, et al. A phase I study of sequential vaccinations with fowlpox-CEA (6D)-Tricom (B7/CAM/LFA3) alone.... Abstract No. 24. 2002 ASCO Annual Meeting.	

Examiner  
Signature

/Sean Aeder/ (04/16/2008)

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.  
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.